Humacyte (HUMA) Competitors $2.50 +0.03 (+1.01%) As of 09:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. EVO, JANX, EWTX, ABCL, ANIP, ETNB, COGT, TVTX, SRPT, and NTLAShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Evotec (EVO), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), AbCellera Biologics (ABCL), ANI Pharmaceuticals (ANIP), 89BIO (ETNB), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), Sarepta Therapeutics (SRPT), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Its Competitors Evotec Janux Therapeutics Edgewise Therapeutics AbCellera Biologics ANI Pharmaceuticals 89BIO Cogent Biosciences Travere Therapeutics Sarepta Therapeutics Intellia Therapeutics Humacyte (NASDAQ:HUMA) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability. Do insiders & institutionals hold more shares of HUMA or EVO? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 5.1% of Humacyte shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, HUMA or EVO? Humacyte has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Do analysts recommend HUMA or EVO? Humacyte presently has a consensus target price of $11.71, suggesting a potential upside of 365.78%. Evotec has a consensus target price of $5.90, suggesting a potential upside of 48.99%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Humacyte is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to HUMA or EVO? In the previous week, Humacyte had 2 more articles in the media than Evotec. MarketBeat recorded 5 mentions for Humacyte and 3 mentions for Evotec. Humacyte's average media sentiment score of 0.50 beat Evotec's score of 0.46 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, HUMA or EVO? Humacyte has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$517K754.59-$148.70M-$0.69-3.64Evotec$862.40M1.63-$212.18MN/AN/A Is HUMA or EVO more profitable? Humacyte has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Humacyte's return on equity of 0.00% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -73.59% Evotec -26.34%-21.51%-10.54% SummaryHumacyte beats Evotec on 13 of the 15 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$388.57M$2.98B$5.42B$9.56BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-3.6317.9729.9025.14Price / Sales754.59177.57372.1776.15Price / CashN/A41.8335.9458.58Price / Book-6.137.238.105.59Net Income-$148.70M-$54.43M$3.26B$265.48M7 Day Performance10.31%0.22%0.65%1.22%1 Month Performance-2.14%5.59%2.43%0.39%1 Year Performance-68.56%9.98%27.70%23.47% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte1.8901 of 5 stars$2.52+1.8%$11.71+365.8%-68.5%$388.57M$517K-3.63150Upcoming EarningsEVOEvotec1.9697 of 5 stars$4.26flat$5.93+39.3%+26.1%$1.51B$862.40M0.004,827Upcoming EarningsGap UpJANXJanux Therapeutics2.2866 of 5 stars$25.55-1.6%$91.89+259.6%-36.0%$1.51B$10.59M-18.7930Earnings ReportEWTXEdgewise Therapeutics2.1912 of 5 stars$14.26+1.0%$40.00+180.5%-18.5%$1.50BN/A-9.2060News CoverageEarnings ReportUpcoming EarningsABCLAbCellera Biologics2.5983 of 5 stars$4.92-3.7%$8.75+77.8%+61.2%$1.47B$28.83M-8.79500News CoverageEarnings ReportANIPANI Pharmaceuticals3.7739 of 5 stars$66.50-1.5%$78.88+18.6%+21.0%$1.44B$614.38M-52.36600News CoverageEarnings ReportETNB89BIO1.5584 of 5 stars$9.53-0.6%$26.43+177.3%+17.0%$1.39BN/A-2.8240News CoverageEarnings ReportCOGTCogent Biosciences3.234 of 5 stars$12.09+0.2%$18.70+54.7%+25.8%$1.38BN/A-6.5780Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTVTXTravere Therapeutics2.0362 of 5 stars$15.40+0.5%$32.14+108.7%+100.8%$1.37B$233.18M-5.48460News CoverageEarnings ReportAnalyst ForecastSRPTSarepta Therapeutics4.6235 of 5 stars$13.86+16.2%$51.42+271.0%-87.2%$1.36B$1.90B-5.151,372Trending NewsEarnings ReportAnalyst ForecastHigh Trading VolumeNTLAIntellia Therapeutics4.2328 of 5 stars$13.11-3.6%$33.37+154.5%-46.2%$1.36B$45.57M-2.51600News CoverageEarnings ReportUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies EVO Competitors JANX Competitors EWTX Competitors ABCL Competitors ANIP Competitors ETNB Competitors COGT Competitors TVTX Competitors SRPT Competitors NTLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts